BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35226658)

  • 1. Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.
    Saglam O; Cao B; Wang X; Toruner GA; Conejo-Garcia JR
    PLoS One; 2022; 17(2):e0264014. PubMed ID: 35226658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
    Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
    Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
    Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong expression of PD-L1 in invasive front of MELF pattern in endometrioid carcinoma.
    Tahara S; Kohara M; Sato K; Morii E
    Pathol Res Pract; 2022 Jan; 229():153699. PubMed ID: 34929601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
    Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
    Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas.
    He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
    Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic characteristics, tumor infiltrating lymphocytes and programed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function.
    Chavez JA; Wei L; Suarez AA; Parwani AV; Li Z
    Int J Gynecol Cancer; 2019 Jan; 29(1):113-118. PubMed ID: 30640692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
    Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
    Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.
    Giordano G; Campanini N; Goldoni M; Rodolfi AM; Brigati F; Merisio C; Berretta R
    Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):468-477. PubMed ID: 28187032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
    Hashimoto T; Kurokawa Y; Takahashi T; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Ikeda JI; Mori M; Doki Y
    Gastric Cancer; 2019 Jul; 22(4):785-792. PubMed ID: 30617648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
    Saglam O; Tang Z; Tang G; Medeiros LJ; Toruner GA
    PLoS One; 2020; 15(9):e0238477. PubMed ID: 32877461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
    Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
    J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.